Business Context and Reporting Period
This Form 8-K was filed by Flora Growth Corp. for an event occurring on April 1, 2024. The provided request metadata identifies Zerostack Corp., but the filing names Flora Growth Corp. as the registrant.
Flora entered into a binding letter of intent with TruHC Holding GmbH to acquire all issued and outstanding shares of TruHC Pharma GmbH.
Transaction Terms and Key Metrics
- Consideration: 2,770,562 Flora common shares with an aggregate deemed purchase price of US$6.4 million.
- First issuance: Shares representing 19.99% of Flora’s issued and outstanding common shares, priced at a deemed US$2.31 per share, subject to execution of a definitive agreement.
- Second issuance: The remaining consideration shares, subject to shareholder approval.
- The filing does not provide current-period revenue, profit, cash flow, margins, debt, cash balances, liquidity, or other operating financial metrics.
Material Changes Versus Prior Comparable Period
The filing does not report comparative financial results or quantify changes from a prior period. The material development is Flora’s proposed acquisition of TruHC Pharma GmbH and the planned issuance of common shares as consideration.
Guidance, Outlook, Risks, and Contingencies
- Flora and the Seller agreed to proceed diligently and in good faith toward negotiating, executing, and delivering a definitive agreement.
- The transaction remains subject to final tax, corporate, and securities law advice for both parties.
- The second share issuance requires shareholder approval.
- The letter of intent is not itself a completed acquisition; closing terms and the definitive agreement remain outstanding.
- Forward-looking statements concern the definitive agreement, transaction completion, share issuances, and shareholder approval. Flora disclaimed any obligation to update these statements.
Important Facts for Investors to Verify
- Whether Flora and TruHC execute a definitive acquisition agreement and on what final terms.
- Whether shareholders approve the second issuance of consideration shares.
- The actual number of shares issued in each step and the resulting dilution to existing shareholders.
- Whether the transaction closes and the timing and financial condition of TruHC Pharma GmbH.
- The discrepancy between the requested company name, Zerostack Corp., and the registrant identified in the filing, Flora Growth Corp.